<b>Introduction</b> A&nbsp;recent systematic review critically appraised prognostic models in COPD and reported that long-term prediction was most accurate when respiratory parameters, such as <i>lung function</i> and <i>dyspnea</i> were combined with systemic factors, such as <i>exacerbations</i>. <b>Objective</b> To describe demographic and clinical characteristics according to GesEPOC 2021 proposal of three high-risk phenotypes: <b>non-exacerbator</b> (mMRC 2-4 or post-bronchodilator FEV₁ &lt;50%) and <b>exacerbator</b> (1 hospitalization or ≥2 moderate exacerbations) <b>non-eosinophilic</b> (&lt;300 cells/mm³) and <b>eosinophilic</b> (≥300 cells/mm³). <b>Methods</b> A retrospective cohort study of outpatients with confirmed COPD attending a disease management program in two specialized centers in Bogota, Colombia (2600 meters above sea level)&nbsp;with 52 weeks of follow-up. <b>Results</b> 197 patients were included (GOLD B=156, D=41); mean age 77.9±7.9 years; 48% were women, and 52% had biomass exposure. Mean FEV₁/FVC 53.4±9.8, mean FEV1 52.7%±20.7, median Charlson comorbidity index 6. There was no difference between groups according to age, risk factors, comorbidities, dyspnea, or BODE index. The <b>eosinophilic&nbsp;exacerbator phenotype</b>&nbsp;was more common in women, higher prevalence of severe airflow obstruction and reversibility in spirometry, and had more frequency of moderate exacerbations and hospitalizations in the follow-up in comparison with the <b>non-eosinophilic exacerbator phenotype</b> (0.92 vs. 0.74). Patients&nbsp;with&nbsp;a <b>non-exacerbator phenotype</b> had the lowest number of exacerbations (no hospitalizations) in the follow-up (0.67). <b>Conclusion</b> In our cohort, there were differences in&nbsp;clinical outcomes between the&nbsp;risk phenotypes&nbsp;proposed by GesEPOC 2021, supporting its clinical utility.